N-(6-amino-5-methyl-3-pyridinyl)-2-[(2R,5R)-2-cyclohexyl-5-methylpiperidin-1-yl]-2-oxoacetamide
C20H30N4O2 — CID 164750802
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-(6-amino-5-methyl-3-pyridinyl)-2-[(2R,5R)-2-cyclohexyl-5-methylpiperidin-1-yl]-2-oxoacetamide
N-(6-amino-5-methyl-3-pyridinyl)-2-[(2R,5R)-2-cyclohexyl-5-methylpiperidin-1-yl]-2-oxoacetamide (PubChem CID 164750802) has the molecular formula C20H30N4O2 and a molecular weight of 358.49 g/mol. Its IUPAC name is N-(6-amino-5-methyl-3-pyridinyl)-2-[(2R,5R)-2-cyclohexyl-5-methylpiperidin-1-yl]-2-oxoacetamide.
Molecular Properties
| Compound Name | N-(6-amino-5-methyl-3-pyridinyl)-2-[(2R,5R)-2-cyclohexyl-5-methylpiperidin-1-yl]-2-oxoacetamide |
|---|---|
| PubChem CID | 164750802 |
| Molecular Formula | C20H30N4O2 |
| Molecular Weight | 358.49 g/mol |
| Exact Mass | 358.24 |
| IUPAC Name | N-(6-amino-5-methyl-3-pyridinyl)-2-[(2R,5R)-2-cyclohexyl-5-methylpiperidin-1-yl]-2-oxoacetamide |
| SMILES | Cc1cc(NC(=O)C(=O)N2C[C@H](C)CC[C@@H]2C2CCCCC2)cnc1N |
| InChI | InChI=1S/C20H30N4O2/c1-13-8-9-17(15-6-4-3-5-7-15)24(12-13)20(26)19(25)23-16-10-14(2)18(21)22-11-16/h10-11,13,15,17H,3-9,12H2,1-2H3,(H2,21,22)(H,23,25)/t13-,17-/m1/s1 |
| InChIKey | JCGGSEKYBKBVBS-CXAGYDPISA-N |
| XLogP | 3.12 |
| TPSA | 88.32 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 2 |
| Heavy Atoms | 26 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 358.49 |
| LogP ≤ 5 | 3.12 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 4 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'diketo_group', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 164750802 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.